메뉴 건너뛰기




Volumn 3, Issue 1, 2013, Pages 1-6

The impact of weight loss among seniors on medicare spending

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC DISEASE; COST BENEFIT ANALYSIS; COST CONTROL; FUNCTIONAL STATUS; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MEDICARE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RISK REDUCTION; WEIGHT REDUCTION;

EID: 84971276093     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/2191-1991-3-7     Document Type: Article
Times cited : (16)

References (16)
  • 3
    • 84971226544 scopus 로고    scopus 로고
    • National Diabetes Fact Sheet
    • American Diabetes Association
    • American Diabetes Association: 2011 National Diabetes Fact Sheet. 2011. http://www.diabetes.org/diabetes-basics/diabetes-statistics/?loc= DropDownDB-stats.
    • (2011) 2011
  • 4
    • 33846878114 scopus 로고    scopus 로고
    • The Health and Cost Consequences of Obesity Among the Future Elderly
    • Lakdawalla DN, Goldman DP, Shang B: The Health and Cost Consequences of Obesity Among the Future Elderly. Health Aff (Millwood) 2005, W5:R30-R41.
    • (2005) Health Aff (Millwood) , vol.W5
    • Lakdawalla, D.N.1    Goldman, D.P.2    Shang, B.3
  • 5
    • 43049125182 scopus 로고    scopus 로고
    • The Financial Burden of Overweight and Obesity among Elderly Americans: The Dynamics of Weight, Longevity, and Health Care Cost
    • Yang Z, Hall AG: The Financial Burden of Overweight and Obesity among Elderly Americans: The Dynamics of Weight, Longevity, and Health Care Cost. Health Serv Res 2008, 43(3):849-868.
    • (2008) Health Serv Res , vol.43 , Issue.3 , pp. 849-868
    • Yang, Z.1    Hall, A.G.2
  • 7
    • 70449517253 scopus 로고    scopus 로고
    • Diabetes Prevention Program Research Group: 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study
    • Diabetes Prevention Program Research Group: 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686.
    • (2009) Lancet , vol.374 , pp. 1677-1686
  • 8
    • 84856388467 scopus 로고    scopus 로고
    • Two year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study
    • Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH: Two year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012, 95(2):297-308.
    • (2012) Am J Clin Nutr , vol.95 , Issue.2 , pp. 297-308
    • Garvey, W.T.1    Ryan, D.H.2    Look, M.3    Gadde, K.M.4    Allison, D.B.5    Peterson, C.A.6    Schwiers, M.7    Day, W.W.8    Bowden, C.H.9
  • 11
    • 84971209269 scopus 로고    scopus 로고
    • Belviq full prescribing information
    • Belviq full prescribing information. 2012. http://us.eisai.com/package_inserts/BelviqPI.pdf.
    • (2012)
  • 12
    • 77956057548 scopus 로고    scopus 로고
    • Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    • Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dynayevich E: Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010, 376:595-605.
    • (2010) Lancet , vol.376 , pp. 595-605
    • Greenway, F.L.1    Fujioka, K.2    Plodkowski, R.A.3    Mudaliar, S.4    Guttadauria, M.5    Erickson, J.6    Kim, D.D.7    Dynayevich, E.8
  • 13
    • 84971356519 scopus 로고    scopus 로고
    • Contrave FDA Advisory Committee Briefing Document (NDA 200063)
    • Contrave FDA Advisory Committee Briefing Document (NDA 200063). 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM235672.pdf+Contrave&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&ie=UTF-8&access=p&oe=UTF-8.
    • (2010)
  • 14
    • 79954561234 scopus 로고    scopus 로고
    • Effects of low-dose controlled-release phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomized, placebo-controlled, phase 3 trial
    • Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW: Effects of low-dose controlled-release phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet 2011, 377:1341-1352.
    • (2011) Lancet , vol.377 , pp. 1341-1352
    • Gadde, K.M.1    Allison, D.B.2    Ryan, D.H.3    Peterson, C.A.4    Troupin, B.5    Schwiers, M.L.6    Day, W.W.7
  • 16
    • 84971290570 scopus 로고    scopus 로고
    • How Obesity Threatens America's Future
    • Fas in Fat
    • Fas in Fat: How Obesity Threatens America's Future. Trust for America's Health; 2011. http://www.rwjf.org/content/dam/web-assets/2011/07/f-as-in-fat.
    • (2011) Trust For America's Health


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.